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Abstract 
 
Background: The pulmonary artery (PA) distends as pressure increases. The ratio of PA to aortic 
(Ao) diameter may be an indicator of pulmonary hypertension and consequently carry prognostic 
information in patients with chronic heart failure (CHF).  
 
Methods: Patients with CHF and control subjects undergoing cardiac magnetic resonance imaging 
(CMRI) were evaluated. The main PA diameter and the transverse axial Ao diameter at the level of 
bifurcation of the main pulmonary artery were measured. The maximum diameter of both vessels 
was measured throughout the cardiac cycle and the PA/Ao ratio was calculated. 
 
Results: 384 patients (mean age 69 years, mean left ventricular ejection fraction 40%, median 
amino terminal pro-brain natriuretic peptide (NTproBNP) 1,010 (IQR: 448-2,262) ng/l) and 38 
controls were included. Controls and patients with CHF had similar maximum Ao and PA 
diameters, and PA/Ao ratio.  
 
During a median follow up of 1,759 days (998-2,269), 181 patients with HF were hospitalised for 
HF or died. Neither PA diameter nor PA/Ao ratio predicted outcome in univariable analysis. In a 
multivariable model, only age and NT-proBNP were independent predictors of adverse events.  
 
Conclusions: the PA/Ao ratio is not a useful method to stratify prognosis in patients with heart 
failure. 
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Introduction 
For patients with chronic heart failure (CHF), pulmonary hypertension (PHT), right ventricular 
(RV) dysfunction and increased venous pressure and congestion are associated with a poor 
prognosis whether or not left ventricular ejection fraction (LVEF) is reduced [1-8]. 
 
An enlarged main pulmonary artery (PA) and an increased pulmonary/aorta (PA/Ao) diameter ratio 
are indirect signs of pulmonary hypertension (PHT) [9-11]. Their clinical and predictive value has 
been mainly studied in patients with respiratory diseases, including chronic obstructive pulmonary 
disease (COPD) [12-14] and pulmonary arterial hypertension [11, 15]. Previous studies suggest that 
the PA/Ao ratio, as assessed on computed tomography (CT), may be a useful measure of pulmonary 
hypertension, especially in patients younger than 50 years [16]. A PA/Ao ratio >1 detected by CT is 
also a powerful predictor of severe COPD exacerbations [12].  However, the clinical and prognostic 
utility of this measure in patients with CHF is unknown. 
 
We therefore studied the association between PA/Ao diameter ratio and both clinical characteristics 
and outcome in patients with HF using cardiac magnetic resonance imaging (CMRI). 
 
Methods 
 
Study population 
This is a single-centre prospective observational study. Between June 2005 and November 2011, 
ambulatory patients referred with suspected HF to a community HF clinic who had undergone 
CMRI as part of their investigation were enrolled. The analysis plan was designed post-hoc: the 
scans were not performed specifically to determine PA/Ao diameter ratio. Patients were followed 
up until 1
st
 June 2015.  Physical examination, routine laboratory tests (including NTproBNP), and 
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electrocardiogram (ECG) were performed on the same day. Heart failure was defined as LVEF 
<50% on CMRI or plasma concentration of amino-terminal pro-B-type natriuretic peptide 
(NTproBNP) >220 pg/ml, consistent with the 2007 ESC consensus statement for diagnosis of heart 
failure with preserved ejection fraction [17].  
 
A congestion score based on lung auscultation (normal, basal, mid zone, or diffuse crepitations), 
jugular venous pressure (not raised, raised 1-4 cm, up to the earlobe), peripheral oedema (none, 
ankles, below or above knees), and liver (not palpable, palpable) with one point attributed for each 
degree of severity was used. Patients with a score ≥3 were defined as being congested [18].  
 
Data regarding deaths and hospitalisations were collected from the hospital’s electronic systems, 
supplemented by information from patients, discharge letters, and their family doctors. Our hospital 
is the only one in the region offering acute medical services. We have access to both primary and 
secondary care records. Outcome was censored at the point of last medical contact in primary or 
secondary care. The vital status of all patients who had no local medical contact in the previous 6 
months was ascertained from national records. The primary outcome was a composite of 
hospitalization for HF and all-cause mortality. Hospitalisations were considered to be HF related if 
the diagnosis was included in the death or discharge documentation, and if the discharge letter 
supported HF as a key reason for admission.   
 
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by 
relevant ethical bodies. Written informed consent was obtained from each patient.  
 
Cardiac magnetic resonance imaging measurements    
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Cardiac magnetic resonance images were acquired using a 1.5 T scanner (either Sigma CV/I, GE 
Medical Systems or Achieva, Philips Medical Systems) equipped with a phased-array coil placed 
over the praecordium. ECG-gated cine acquisitions were performed during breath-hold (in 
expiration), using a steady state free precession pulse sequences in two standard long axes and 
multiple short-axis slices, with slice thickness of 8 mm and inter-slice distance of 2 mm from the 
base to the apex of the heart.   
 
Images were analysed offline using QMass MR software (MEDIS, Leiden, The Netherlands). The 
multi-slice, short-axis cine data-sets were analysed to calculate left ventricular (LV) and right 
ventricular (RV) volumes and masses. Endocardial and epicardial borders were traced manually by 
an experienced observer using end-diastolic and end-systolic frames in contiguous short-axis slices. 
LV end-diastolic (EDV) and end-systolic (ESV) volumes were calculated using summation of area × 
[slice thickness + interslice gap] for each slice (Simpson's method), which were then used to calculate 
LVEF and LV mass. Papillary muscles were excluded from LV volume measurements and included 
in mass calculations. The interventricular septum was considered to be part of the LV. RV volumes, 
mass and EF were calculated in a similar fashion. Left atrium (LA) maximum volume was measured 
at the frame just before mitral valve opening in the 4 chamber long axis view. Mitral and tricuspid 
regurgitation volume was visually graded as none or trivial (0), mild (1) or moderate or worse (2). 
Intra and inter-variability data for CMRI measurements in our department have been reported [19]. 
 
The transverse axial diameter of the main pulmonary artery and the ascending aorta at the level of 
the bifurcation of the main pulmonary artery were measured by a single research fellow specializing 
in cardiovascular imaging (AU). The PA/Ao ratio was calculated as the ratio of their maximum 
diameters during the cardiac cycle (figure 1).  
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Statistical analysis 
Categorical data are presented as number and percentages; normally distributed continuous data as 
mean ±SD; non-normally distributed variables as median and interquartile range (IQR). Independent 
samples t-tests, one-way ANOVA and Kruskal-Wallis tests were used to compare continuous 
variables between groups, and chi-squared tests were used for categorical variables.  
 
Simple
 
and multiple linear regression models were used to identify variables associated with PA/Ao 
ratio.  Only the variables associated with PA/Ao in univariable analysis were entered into the 
multivariable analysis. Log transformation of NTproBNP and urea were used to satisfy the model 
assumptions. Associations between variables and prognosis were assessed using Cox proportional 
hazards models. Only variables associated with outcome (p<0.1) in univariable analysis were 
entered into multivariable models. Treatment variables were not included in the model as these are 
confounded by indication (patients who are sicker may be more likely to receive some treatments 
and less likely to tolerate others) and vary over time. Kaplan–Meier curves with the log-rank 
statistic were used to illustrate outcome. Analyses were performed using SPSS (v22) and Stata 
software, a two-sided P-value of 0.05 was considered statistically significant.  
 
Results 
 
Patient characteristics 
Of 422 patients enrolled, 384 met the criteria for heart failure. The other 38 subjects were taken to 
be controls. Compared to controls, patients with HF were older, and were more likely to have 
ischaemic heart disease (IHD) and atrial fibrillation (AF). Their demographic and clinical 
characteristics are shown in Table 1.  
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PA and Ao diameters, and their ratio, were similar in patients with HF and controls.  Amongst 
patients with HF, those in the highest tercile of PA/Ao ratio (greater PA/Ao ratio) were younger, 
had more severe symptoms and overall more congestion than the other two terciles.  
 
Those in the highest PA/Ao tercile had both larger PA diameter and smaller Ao diameters on 
average. They also had larger LA and RV end diastolic volumes (Table 1).   
 
Of the MRI variables, increasing RVEDV was most strongly associated with increasing PA/Ao 
ratio. Only decreasing age, and increasing LA and RV volumes were independently associated with 
increasing PA/Ao ratio (table 2). In patients with LVEF ≤ 40%, only decreasing age independently 
predicted a greater PA/Ao ratio, whilst in patients with LVEF > 40%, decreasing age and creatinine 
levels were associated with increasing PA/Ao ratio.  
 
PA/Ao ratio was similar in men and women and in patients with or without COPD. Patients with 
more severe symptoms and congestion, and those with a clinically higher JVP had a greater PA/Ao 
ratio (Supplementary Table 1). 
 
PA/Ao ratio and outcome 
During a median follow-up of 1,759 days (IQR:  998-2,269) days (censored at time of first event) 
the primary outcome (hospitalization for HF and all-cause mortality) was reached by 47% (n=181) 
of patients with CHF and 29% (n=11) of controls. Neither minimum nor maximum PA and Ao 
diameter, nor their ratio, were associated with adverse outcomes in univariable analysis, even when 
PA diameter was indexed for body surface area (BSA; BSA is closely related to an adverse outcome 
in this, and in a larger dataset [20]). The only CMRI predictors of adverse events were greater LA 
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volume, and lower LA and RV ejection fractions. In a multivariable model, including CMRI 
variables, only increasing age and NT-pro BNP were independent predictors of an adverse outcome 
(table 3). 
There was no difference in outcome between patients who had PA/Ao >1 compared to <1 (HR: 
1.07, 95% CI: 0.74-1.60, p=0.67) or between patients who had PA/Ao >0.9 versus <0.9 ((HR: 1.02, 
95% CI: 0.76-1.37, p=0.90). Even when patients with a dilated ascending Ao (>4 cm) were 
excluded (n=25), results did not change substantially (PA/Ao >1versus <1 (HR: 1.05, 95% CI: 0.71-
1.56, p=0.80); PA/Ao >0.9 versus <0.9 (HR: 0.97, 95% CI: 0.71-1.30, p=0.82). There was no 
difference in the primary outcome amongst the three PA/Ao terciles (figure 2). 
During the study 147 patients died; neither minimum nor maximum PA (HR: 0.99, 95% CI: 0.95-
1.03, p=0.55), maximum Ao diameter (HR: 0.99, 95% CI: 0.96-1.03, p=0.75), nor their ratio (HR: 
0.82, 95% CI: 0.24-2.78, p=0.75), were associated with all-cause mortality.  
 
Discussion  
 
Measurement of the PA/Ao ratio may be of prognostic value in patients with respiratory disease 
[12, 21]. However, although we found that for patients with HF, a higher PA/Ao ratio measured by 
CMRI was associated with more clinical evidence of congestion, and larger left atrial and right 
ventricular volumes, it was not an important predictor of an adverse outcome.  
Nakanishi and colleagues studied 1,326 patients undergoing coronary CT angiography for suspected 
coronary artery disease [22]. Consistent with our results, those with larger PA/Ao ratio were 
younger, and had a smaller aorta, but Nakanishi found that an elevated PA/Ao ratio (≥ 0.9) was an 
independent predictor of mortality. However, there were few death (58 compared to 147 in our 
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study) with only 15 deaths in patients with a PA/Ao >0.9. They excluded patients with a dilated 
aorta (>4 cm) but excluding such patients did not improve prediction in our analysis. 
There is a linear association between aortic size and increasing age [23], and increasing aortic size 
is associated with decreased distensibility [24]. Our finding of an inverse correlation between 
PA/Ao ratio and age is consistent with a previous study of 3,176 patients from the Framingham 
Heart Study which showed that the PA/Ao was lower in older participants [25].  
 
Limitations  
This was a single centre study and a retrospective analysis of data collected primarily for other 
purposes. Our findings should be prospectively tested before being considered definitive.  The 
population enrolled in our study is not entirely representative of the heart failure population.  Older 
patients with many co-morbidities and more advanced heart failure who might have a more dilated 
pulmonary artery are less likely to be referred for a CMRI, due to frailty, or contra-indications to a 
CMRI, such as an implanted pacemaker. Some authors might not accept an NTproBNP >220 pg/ml 
as diagnostic for heart failure with preserved ejection fraction, although it is consistent with ESC 
consensus statement available when the study was conceived [17].   
Some might also argue that a control group consisting of symptomatic individuals with comorbidities 
which might cause heart failure is not appropriate for the initial evaluation of a method to stratify 
prognosis. Others will argue that a control population comprising conditions closely associated with 
heart failure, such as ours, is more relevant. The reader should decide. A control group of perfectly 
healthy older people would certainly be of interest, but unfortunately it was not locally available.  
PA and Ao diameters were measured from axial images which in some cases were not planned 
exactly in line with the vessel orientation.  This could have led to occasional under- or over- 
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estimations of the main artery diameters.   
Invasive or non-invasive echocardiographic evaluation of PA pressure was not done at the time of the 
CMRI, so we do not know how many patients had PHT in this study.  
 
Conclusions 
Our findings suggest that a higher PA/Ao ratio is not a useful indicator of a poorer prognosis in 
patients with CHF.  Publication of results from other centres would be of interest to confirm or refute 
our findings.    
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Legend to figures. 
Figure 1: An axial cardiac magnetic resonance imaging (cMRI) image at the level of pulmonary 
artery (PA) bifurcation, where measurements of the diameter of the main PA (in blue) and the 
diameter of the aorta (Ao, in red) were obtained to calculate PA/Ao ratio.   
 
Figure 2: Kaplan Meier curve for the primary outcome of death from all causes and heart failure 
hospitalizations. There was no difference in the primary outcome for patients among the three PA/Ao 
terciles. 
PA/Ao Ratio 
  
 
No definite evidence 
of Heart Failure 
(38) 
 
Evidence of Heart 
failure 
 
(384) 
 
 
P-value  
 
PA/Ao 
Tercile 1 
(128) 
PA/Ao 
Tercile 2 
(128) 
PA/Ao 
Tercile  3 
(128) 
 
P-value  
 
 
 
Max Ao- mm 34.3 (31.4 - 36.9) 33.5 (30.8-36.3) 0.998 35.4 (33.1-38.4) 33.6 (31.2-35.7) 31.7 (28.9-34.0) <0.001 
Min Ao- mm 33.9 (30.4-36.4) 32.5 (29.5-35.1) 0.891 34.5 (31.9-37.1) 32.7 (30.19-34.7) 30.0 (28.2-33.1) <0.001 
Max PA- mm 28.8 (26.2-33.8) 29.4 (26.7-32.4) 0.934 26.3 (24.3- 28.8) 29.5 (27.3 32.1) 32.5 (29.7-35.7) <0.001 
Min PA- mm 25.1 (22.5-28.8) 25.9 (23.5-28.7) 0.585 23.8 (21.7-26.0) 25.9 (23.7- 28.0) 28.8 (26.1-31.5) 0.024 
PA/Ao ratio 0.90 (0.77-0.99) 0.87 (0.79-0.97) 0.975 0.76 (0.71-0.79) 0.88 (0.85-0.92) 1.00 (0.97-1.07) NA 
Max PA/BSA 14.5 (13.1-15.8) 15.3 (13.9-16.7) 0.090 14.1 (12.6-15.2) 15.3 (14.0-16.4) 16.6 (15.4-18.3) <0.001 
Demographics 
Age – years  62 (11) 69 (11) 0.009 71 (9) 68 (11) 63 (12) <0.001 
Sex – male (%) 27 (71) 312 (81) 0.131 109 (85) 101 (79) 102 (80) 0.377 
IHD – no. (%) 17 (44) 252 (65) 0.011 88 (69) 86 (67) 78 (61)  0.379 
DM - no. (%) 9 (24) 104 (27) 0.652 26 (20) 38 (30) 40 (31) 0.104 
Hypertension - no. (%) 23 (61) 196 (51) 0.264 70 (55) 68 (53) 58 (45) 0.275 
COPD - no. (%) 4 (11) 27 (7) 0.431 11 (9) 8 (6) 8 (6) 0.699 
NYHA class - no. (%)        
I 13(34) 77 (20) 
0.080 
28 (22) 27 (21) 22 (17)  
0.019 
 
II 12(32) 180 (47) 72 (56) 53 (41) 55 (43) 
III 13 (34) 140 (33) 28 (22) 48 (38) 51 (40) 
SBP – mmHg 135 (22) 133(25) 0.557 136(25)  133(24)  129(26) 0.083 
Heart rate – bpm 70 (14) 67 (14) 0.172 67(12) 66 (15) 68 (16) 0.588 
Atrial Fibrillation (%) 1 (3) 86 (22) 0.004 28 (22) 33 (26) 25 (29) 0.480 
Congestion > 3 – no.(%) 3 (8) 46 (12) 0.477 6 (5) 19 (15) 21 (16) 0.008 
JVP – no. (%)        
raised 1-4 cm 0 (0) 29 (7) 
0.167 
4 (3) 9 (7) 16 (13) 
0.026 
up to the earlobe 0 (0) 5 (1) 0 (0) 3 (2) 2 (2) 
BMI - kg/m2 32 (6) 28 (5) 0.002 28 (5) 29(5) 29 (6) 0.142 
BSA –  m2 2.0 (0.2) 1.9 (0.2) 0.086 1.9 (0.2) 2.0 (0.2) 2.0 (0.2) 0.313 
Blood test 
Haemoglobin – g/dl 14.1 (1.6) 13.5 (1.7) 0.032 13.7 (1.7) 13.3 (1.8) 13.6 (1.8) 0.221 
Creatinine –μmol/l 94 (82-103) 99 (82-122) 0.012 102 (88-124) 105 (78-111) 92 (78-111) 0.036 
Urea – mmol/l 5.6 (4.5-6.8) 6.5 (5.1-8.6) 0.023 7.0 (5.0-8.9) 6.5 (5.2-8.2) 6.2 (4.8-8.5) 0.387 
Albumin -  g/l 39 (3) 38 (3) 0.067 38 (3) 38 (3) 38 (4) 0.355 
Bilirubin -  μmol/l 14 (7) 16 (6) 0.315 16 (7) 15 (7) 16 (6) 0.371 
NT-proBNP – ng/l 97 (49-154) 1010 (448-2262) <0.001 875 (411-2326) 942 (449-2079) 1137 (463-2262) 0.959 
Drugs 
Beta-blockers - no. (%) 19 (50) 306 (80) <0.001 100 (78) 104 (81) 102 (80) 0.824 
PA/Ao Ratio 
 
 
 
 
Table 1: Characteristics of patients by diagnosis and, for patients with heart failure by terciles of pulmonary/aorta ratio. Data are mean and 
standard deviation if the variable is normally distributed and median and inter-tercile range if not. The statistical difference between variables is 
given for the comparison between patients with and without heart failure, and between terciles of PA/Ao only in patients with heart failure. List 
of abbreviation used: PA – Pulmonary Artery; Ao – Aorta; PA/Ao – Pulmonary/Aorta ratio; BSA: Body Surface Area; IHD - Ischemic Heart 
Disease; DM – Diabetes Mellitus; COPD - Chronic Obstructive Pulmonary Disease; NYHA – New York Heart Association; SBP - Systolic 
Blood Pressure; JVP - Jugular Vein Pressure; BMI - Body Mass Index; NT-proBNP - N-terminal B-type natriuretic peptide; ARB - Angiotensin 
receptor blocker; MRI- Magnetic Resonance Imaging; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection 
Fraction; LV: Left Ventricle; LA – Left Atrium; LAEF - Left Atrial Ejection Fraction; RVEDV - Right Ventricle End Diastolic Volume; RVEF 
– Right Ventricular Ejection Fraction; RV - Right Ventricle. For right ventricular size and function, only 11 measurements were available for 
patients considered not to have heart failure and 313 for those considered to have heart failure. 
Ace-Inhibitors or ARB - no. (%) 28 (74) 336 (88) 0.018 113 (88) 110 (86) 113 (88) 0.807 
Aldosterone Antagonist -no. (%) 10 (26) 139 (36) 0.224 45 (35) 48 (38) 46 (36) 0.924 
Loop diuretics - no. (%) 16 (42) 263 (69) 0.001 81 (63) 90 (70) 92 (72) 0.289 
MRI measurements 
LVEDV – ml 135 (113-156) 207 (163-254) <0.001 200 (158- 242) 210 (162-265) 211 (172-257) 0.111 
LVEF - % 60 (7) 40 (13) <0.001 39 (31-48) 40 (31-46) 37 (29-48) 0.451 
LV mass - g 115 (97-139) 145 (122-177) <0.001 148 (124-181) 145 (123-179) 145 (120-174) 0.731 
MAX LA volume – 4c - ml 69 (53-90) 106 (77-138) <0.001 96 (67-127) 107 (79-140) 114 (79-148) 0.036 
LAEF – 4ch - % 54 (48- 58) 40 (24-52) <0.001 42 (27-53) 41 (27-52) 37 (20-52) 0.371 
RVEDV – ml   154 (122-170) 146 (119-176) 0.518 135 (111-161) 147 (116-178) 156 (126-111) 0.005 
RVEF - % 56 (49-58) 52 (44-60) 0.495 54 (45-60) 54 (47-60) 51 (40-60) 0.084 
RV mass - g 46 (40-57) 51 (42-63) 0.341 49 (40-59) 51 (43-64) 54 (45-69) 0.017 
Mitral regurgitation (%)    
 
0.030 
   
 
0.769 
Mild 8 (21) 149 (39) 48 (38) 46 (36) 55 (43) 
Moderate/Severe  0 (0) 13 (3) 4 (3) 4 (3) 5 (4)  
Tricuspid regurgitation (%)    
 
0.700 
   
0.384 Mild 8 (21) 100 (26) 28 (22) 32 (25) 40 (32) 
Moderate/Severe  0 (0) 2 (1) 0 (0) 1 (1) 1 (1) 
PA/AO Ratio 
 
 
 
Variables Univariable analysis Multivariable analysis 
Overall 
Multivariable analysis 
LVEF <40% 
Multivariable analysis 
LVEF >40% 
 Correlation 
coefficient 
p-value 
Unstandardized 
Coefficients 
 (95% CI) 
T stat 
 
p-value 
Unstandardized 
Coefficients 
with 95% CI 
T stat 
 
p-value 
Unstandardized 
Coefficients 
with 95% CI 
T stat 
 
p-value 
Age - year -0.311 <0.001 -0.004 (-0.005,-0.003) 
-0.005 (-0.006,-0.003) 
-5.855; <0.001 
-5.994; <0.001 
-0.005 (-0.007,-0.003) 
-0.005 (-0.007,-0.003) 
-4.776; <0.001 
-4.615; <0.001 
-0.003 (-0.005,-0.002) 
-0.004 (-0.006,-0.001) 
-3.723; <0.001 
-3.165; 0.002 
SBP – mmHg -0.108 0.035       
Heart rate - bpm 0.046 0.37       
BMI - kg/m
2
 0.042 0.41       
BSA - m
2
 0.032 0.53       
Creatinine –μmol/L  -0.095 0.06     0.000 (-0.001,0.000) 
- 
-1.976; 0.05 
- 
Urea – mmol/l  -0.012 0.81       
Haemoglobin - g/dl  -0.034 0.50       
Albumin – g/l -0.019 0.71       
Bilirubin – μmol/l 0.008 0.87       
Log(NT-proBNP) 0.028 0.058       
LVEDV – ml 0.108 0.034     - 
-0.001 (-0.001,0.000) 
- 
-2.467; 0.015 
LVEF - % -0.047 0.36       
LV mass -g -0.046 0.37       
LA Max  – 4ch – ml 0.124 0.016 0.000 (0.000-0.001) 
- 
2.623; 0.009 
- 
    
LAEF – 4ch – % -0.097 0.060       
RVEDV - ml 0.244 <0.001 - 
0.001 (0.000-0.001) 
- 
2.484; 0.014 
  - 
0.001 (0.000,0.002) 
- 
3.216; 0.002 
RVEF - % -0.148 0.009       
RV mass - g 0.133 0.019       
PA/AO Ratio 
 
 
Table 2:  Variables associated with PA/Ao ratio in patients with heart failure (n=384). Results were obtained from univariable and multivariable 
linear regression models. The first column on the left (Univariable analysis) represents the correlation between PA/Ao ratio and the variables 
studied. The column for the multivariable analysis (centre) shows the coefficients for slope of the linear relation between all the variables 
independently associated with PA/Ao for the overall population of patients with heart failure excluding (top; R
2
=0.13, Adjusted R
2
=0.11) or 
including (bottom; R
2
=0.18, Adjusted R
2
=0.15) measures of RV function (available for 313 patients only). On the right, the two different models 
were repeated for patients with LVEF < 40% (RV excluded, R
2
=0.16, Adjusted R
2
 =0.13; RV included, R
2
=0.17, Adjusted R
2
 =0.13) and with 
LVEF> 40% (RV excluded, R
2
=0.13, Adjusted R
2
 =0.10; RV included, R
2
=0.25, Adjusted R
2
 =0.19).  Variables included in multivariable 
models: age, LVEDV, LA max 4ch, SBP, Creatinine, Log NTproBNP (+ RVEDV, RVEDM, RVEF). 
 
List of abbreviations used: LVEF – Left Ventricular Ejection Fraction; SBP - Systolic Blood Pressure; BMI - Body Mass Index; BSA – Body 
Surface Area; NTproBNP - N-terminal B-type natriuretic peptide; LVEDV - Left Ventricle End Diastolic Volume; LV- Left Ventricle; LA- Left 
Atrium; LAEF- Left Atrial Ejection Fraction; RVEDV- Right Ventricular End Diastolic Volume; RVEF- Right Ventricular Ejection Fraction; 
RV Right Ventricle.  
 
 
 
 
 
Variables 
 
Univariable analysis 
 
Multivariable analysis 
 
 
HR (95% CI) 2 p-value HR (95% CI) 2 p-value 
Clinical data       
Age - year 1.04 (1.03-1.06) 26.99 <0.001 1.02 (1.00-1.04) 5.89 0.015 
Sex (Men) 1.07 (0.89-1.29) 0.49 0.48    
NYHA class (III vs. I/II) 1.58 (1.17-2.14) 9.04 0.003    
IHD (yes vs no) 1.28 (0.93-1.77) 2.28 0.13    
DM (yes vs no) 1.14 (0.82-1.58) 0.61 0.44    
COPD (yes vs no) 1.56 (0.95-2.58) 3.10 0.078    
AF (yes vs no) 1.06 (0.75-1.51) 0.11 0.74    
SBP – mmHg 0.99 (0.99-1.00) 0.16 0.69    
Heart rate - bpm 1.00 (1.00-1.01) 0.63 0.43    
BMI - kg/m
2
 0.99 (0.96-1.02) 0.29 0.59    
BSA - m
2
 0.41 (0.22-0.77) 7.74 0.005    
Congestion (>3 vs <3) 1.55 (1.01-2.37) 4.05 0.044    
JVP (>1 vs 0) 1.09 (0.65-1.83) 0.11 0.74    
Blood Test       
Creatinine –μmol/L  1.01 (1.00-1.01) 21.50 <0.001    
Urea – mmol/l  1.09 (1.05-1.12) 24.94 <0.001    
Haemoglobin - g/dl  0.82 (0.76-0.90) 19.91 <0.001    
Albumin – g/l 0.92 (0.89-0.95) 19.54 <0.001    
Bilirubin – μmol/l 1.00 (0.98-1.01) 0.27 0.60    
Log(NT-proBNP) 2.44 (1.79-3.32) 32.24 <0.001 1.66 (1.50-2.41) 7.18 0.007 
MRI data 
LVEDV – ml 1.00 (0.99-1.01) 1.19 0.28    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:  Univariable and multivariable Cox regression models for a combined endpoint of all-cause mortality and admissions for heart failure 
in patients with HF (n = 384 patients with heart failure who had 181 events during a median FU of 1759 (IQ 998-2269) days). Measurements of 
right ventricular size and function were not included in the multivariable analysis because these were available for only 313 patients (82%) with 
HF. LAEF only for patients in sinus rhythm with available data (n=298). Variables entered in multivariable models: Age, NYHA III vs I/II, 
COPD, BSA, Congestion, creatinine, Haemoglobin, Albumin, Log (NT-proBNP), LA max. List of abbreviation used: NYHA – New York Heart 
Association; IHD - Ischemic Heart Disease; DM – Diabetes Mellitus; COPD - Chronic Obstructive Pulmonary Disease; AF – Atrial Fibrillation; 
SBP - Systolic Blood Pressure; BMI - Body Mass Index; BSA: Body Surface Area; JVP – Jugular Vein Pressure; NT-proBNP - N-terminal B-
type natriuretic peptide; LVEDV - Left Ventricle End Diastolic Volume; LVEF – Left Ventricular Ejection Fraction; LV -  Left Ventricle; LA – 
Left Atrium; LAEF – Left Atrial Ejection Fraction; RV – Right Ventricle; PA – Pulmonary Artery.   
 
 
LVEF - % 0.99 (0.98-1.00) 2.47 0.12    
LV mass -g 1.00 (0.99-1.01) 0.97 0.32    
LA Max  – 4ch – ml 1.01 (1.00-1.01) 4.44 0.035    
LAEF – 4ch – % 0.98 (0.97-0.99) 19.39 <0.001    
RVEDV - ml 0.99 (0.99-1.00) 1.32 0.25    
RVEF - % 0.99 (0.97-1.00) 3.96 0.047    
RV mass - g 1.00 (1.00-1.01) 0.65 0.42    
Min aorta- mm 0.99 (0.97-1.03) 0.11 0.75    
Max aorta- mm 0.99 (0.95-1.02) 0.75 0.39    
Max Pulmonary- mm 0.99 (0.96-1.03) 0.12 0.73    
Min Pulmonary- mm 0.99 (0.98-1.01) 0.47 0.49    
Pulmonary/Ao ratio 1.20 (0.41-3.49) 0.12 0.73    
Max PA/BSA 1.05 (0.99-1.11) 2.32 0.13    
Group PA/Ao ratio 
 Characteristic 
Absent 
Characteristic 
Present 
P value 
Male Sex  0.90 (0.12) 0.88 (0.14) 0.27 
Diabetes Mellitus 0.88 (0.14) 0.90 (0.11) 0.36 
COPD  0.89 (0.13) 0.87 (0.14) 0.44 
IHD  0.91 (0.12) 0.88 (0.14) 0.06 
NYHA III/IV 0.88 (0.14) 0.91 (0.12) 0.03 
Congestion >3  0.88 (0.14) 0.93 (0.11) 0.006 
JVP >1 0.88 (0.13) 0.94 (0.11) 0.004 
Atrial fibrillation 0.89 (0.14) 0.88 (0.12) 0.68 
Loop Diuretics 0.88 (0.14) 0.89 (0.13) 0.23 
Mitral Regurgitation 0.88 (0.14) 0.89 (0.13) 0.50 
Tricuspid Regurgitation 0.88 (0.14) 0.90 (0.12) 0.23 
 
Table 1 Supplementary: Pulmonary/Aorta Ratio in patients with heart failure 
according to absence or presence of various patient and MRI characteristics. List of 
abbreviation used: PA/Ao- Pulmonary/Aorta; COPD - Chronic Obstructive 
Pulmonary Disease; IHD - Ischaemic Heart Disease; NYHA – New York Heart 
Association; JVP- Jugular Vein Pressure. 
 
 
 
